Eli Lilly Remains Well Positioned for Industry-Leading Growth, Buoyed by Cardiometabolic Drugs

Sector Director

Damien Conover

Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Following a very steep patent cliff in 2014, Lilly's growth prospects have improved as the company is launching several new blockbusters and patent losses are fading.

Lilly's internal pipeline is well positioned to mitigate the patent losses during the next decade. The company tends to spend a low- to mid-20s percentage of its sales on financing the development efforts of new drugs, much higher than the high-teens industry average. The robust pipeline is a result of Lilly's strong commitment to research. We believe cardiometabolic drugs Mounjaro, Trulicity, and Jardiance and immunology drug Taltz along with cancer drug Verzenio hold the highest sales potential of Lilly's currently launched drugs. Further, pipeline drugs lebrikizumab (atopic dermatitis), mirikizumab (immunology), and donanemab (Alzheimer's) hold major blockbuster potential. 

Lilly's strong entrenchment in insulin production should also help the company deal with patent losses. Unlike traditional drugs, Lilly's insulin drugs are very hard to copy by generics and create barriers to entry for noninsulin producers because of the large up-front investments needed to create scale efficiencies. A new weekly insulin in late-stage development offers another avenue of growth in this mature market.

The company is taking a hard look at its bottom line. Through a combination of cost savings and expected top-line growth, Lilly aims to expand operating margins over the next several years, which we believe is achievable. Lilly expects to increase gross margins through productivity initiatives and greater capacity utilization. Overall, we view the strong traction of recently launched high-margin drugs in several indications as supporting the overall profitability gains.

Business Strategy & Outlook

Patents, economies of scale, and a powerful distribution network support Eli Lilly’s wide moat. Lilly's patent-protected drugs carry strong pricing power, which enables the firm to generate returns on invested capital in excess of its cost of capital. Further, the patents give the company time to develop the next generation of drugs before generic competition arises. Lilly’s diversified product portfolio means the company’s top drugs represent only a moderate amount of total sales, with the largest drug, Trulicity, representing almost 20% of total sales, which sets up manageable cash flow declines as new products mitigate the generic competition. Also, Lilly’s operating structure allows for cost-cutting after patent losses to reduce the margin pressure from lost high-margin drug sales. Overall, Lilly's established product line creates the enormous cash flows needed to fund the average $800 million in development costs per new drug. In addition, the company's powerful distribution network sets up the company as a strong partner for smaller drug companies that lack Lilly's resources. Lilly's entrenched insulin franchise creates an added layer of competitive advantage, as interchangeable insulin competition seems many years away due to the complexity of gaining generic approval for insulin and the high cost to build the needed economy of scale for insulin production. Also, Lilly's recently launched biologic drugs create higher hurdles over traditional small molecule for biosimilars to gain market share following the eventual patent expirations.

We think the firm does face environmental, social, and governance risks, particularly related to potential U.S. drug price-related policy reform (close to 60% of total sales are generated by prescription drugs sales in the U.S.) to increase access by lowering drug prices. Ongoing product governance issues (including litigation related to side effects and patents) also weigh on the company. While we have factored these threats into our analysis, we don't see them as material to our moat rating for Eli Lilly.

Wide

Economic Moat

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DiCE Molecules Holding LLC

Dice is a biopharmaceutical company that uses a proprietary technology platform to develop new oral therapeutic drugs for autoimmune diseases.

Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push

Nationwide effort to inform people living with diabetes about how to access affordable insulin and give back to the diabetes community INDIANAPOLIS , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is teaming up with the American Diabetes Association® (ADA) and Adam Duvall, American professional baseball player, to launch a nationwide effort to increase awareness of insulin affordability solutions for all people living with diabetes. Lilly's Tap the Cap campaign underscores how easy it is for people with diabetes to tap Lilly's monthly out-of-pocket insulin cap and access $35 insulin*.

Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"

Lilly said its acquisition of Dice for $48 a share would allow it to leverage the group's developing treatments for chronic diseases in immunology.

Eli Lilly to Buy Dice Therapeutics in $2.4 Billion Autoimmune Disease Push

Dice Therapeutics Inc. DICE stock is up by 40% in premarket trades Tuesday after it agreed to be purchased by Eli Lilly & Co. LLY for $48 a share in a deal that values the immunology company at about $2.4 billion. The price values Dice at a 40% premium over the 30-day, volume-weighted average trading price of its stock as of June 16.

Dice Therapeutics rallies as it agrees to be bought by Lilly

Eli Lilly and Co will buy Dice Therapeutics Inc in an all-cash deal worth about $2.4 billion to boost its autoimmune drug portfolio, the companies said on Tuesday.

Eli Lilly to buy Dice Therapeutics in $2.4 billion deal

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc. (NASDAQ: DICE) today announced a definitive agreement for Lilly to acquire DICE.

Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology

Results from a post-approval study show that treatment with Lilly's (LLY) Emgality failed to achieve statistical superiority over Pfizer's Nurtec ODT in preventing episodic migraine in adults.

Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT

Eli Lilly said on Friday its drug Emgality did not meet the primary goal of superiority to Pfizer Inc's Nurtec ODT in prevention of episodic migraine in a post-approval study.

Eli Lilly's migraine drug fails to meet main goal in post-approval study

Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality performed numerically better than the active comparator on key secondary endpoints of the CHALLENGE-MIG trial The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments  INDIANAPOLIS , June 16, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of the CHALLENGE-MIG clinical trial of Emgality ®  (galcanezumab-gnlm) and Nurtec ®  ODT (rimegepant orally disintegrating tablet), the first and only trial of its kind comparing two calcitonin gene-related peptide (CGRP) antagonist therapies. Emgality did not meet the study's primary endpoint, defined as statistical superiority to Nurtec ODT on the percentage of participants achieving a 50% or greater reduction in monthly migraine headache days.

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

Brookfield Renewable Partners

Tesla

Brookfield boasts high-quality assets spanning wind, solar, hydroelectric, and other sustainable projects. Eli Lilly is staking out dominant positions in three huge areas: diabetes, obesity, and Alzheimer's.

3 Top Stocks to Buy and Hold for the Next Decade

Biotech and pharma companies are evaluating how AI could make their businesses better. The CEO of Eli Lilly said he expects AI to massively change the productivity of the workplace.

The CEO of pharma giant Eli Lilly shares 3 ways AI could transform his industry

Eli Lilly inked a gene-editing collaboration with Verve Therapeutics that gave the young biotech "pharma validation."

Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million

Novo Nordisk

Eli Lilly and Novo Nordisk are among the leaders in diabetes and obesity care. Both companies will continue to makes important strides in these two areas.

2 Market-Beating Stocks With More Upside Potential

Fortinet

Alphabet

Royal Caribbean Cruises

United Continental Hlds

Zscaler

Evercore ISI strategist Julian Emanuel looked for stocks “the last buyers have yet to buy.” High short interest is one factor.

Earnings Momentum Power: 6 Names With Room to Run

Ricks said the "biggest problem" with the IRA provision stems from a difference in timeline for negotiating prices on two different types of drugs.

Eli Lilly CEO says Medicare price negotiations could harm drug development

Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 4:20 PM ET Company Participants Anat Ashkenazi - Chief Financial Officer Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Let's kick off the afternoon session here.

Eli Lilly and Company (LLY) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

CRISPR Therapeutics

CRISPR Therapeutics' fortunes may soon change for the better. Eli Lily with its strong pipeline has a favorable outlook ahead.

2 Biotech Stocks That Could Help Make You a Fortune

This week Lilly surpassed Johnson & Johnson to become the world's largest Pharma by market cap. That is quite astonishing given JNJ drove $95bn of revenues last year, compared to Lilly's $28bn. Pharma valuations are based on "jam tomorrow", however, and in Tirzepatide Lilly may have the world's first $100bn per annum selling drug.

Eli Lilly: Most Valuable Global Pharma Thanks To Tirzepatide's Mind-Blowing Possibilities

C3.ai

Mullen Automotive

NVIDIA

O'Reilly Automotive

Shopify

Figuring out which growth stocks to sell may be the last thing on your mind right now. After all, rising hopes for a pivot on interest rates by the Federal Reserve, plus secular growth trends such as accelerating adoption of artificial intelligence (or AI) have provided a massive boost for shares in fast-growing companies lately.

7 Growth Stocks to Sell in June Before They Crash and Burn

Eli Lilly & Co. LLY, +1.64% on Friday released new clinical trial data on treatments for certain types of early breast cancer and mantle cell lymphoma. New analysis from a late-stage trial of Verzenio in node-positive, high risk early breast cancer showed that the treatment in combination with endocrine therapy improved invasive disease-free survival rates by 5.9% in people 65 and older and 6.4% in patients under 65.

Eli Lilly releases new data on breast cancer, lymphoma treatments

New analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in node-positive, high risk early breast cancer show similar efficacy across age groups and in patients who had dose adjustments with benefit maintained at four-year follow-up; overall quality of life during the Verzenio treatment period shown to be similar to endocrine therapy alone Updated data from the Phase 1/2 BRUIN trial of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory MCL continue to demonstrate durable efficacy and no newly identified safety signals INDIANAPOLIS , June 2, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib; CDK4/6 inhibitor) and Jaypirca™ (pirtobrutinib; non-covalent (reversible) BTK inhibitor) data to be presented at the 2023 ASCO® Annual Meeting in Chicago, June 2 – 6, 2023. Presentations include new analyses from the Phase 3 monarchE trial of two years of Verzenio treatment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC) and updated data from the Phase 1/2 BRUIN trial for an approved use of Jaypirca in patients with covalent BTK inhibitor pre-treated relapsed or refractory mantle cell lymphoma (MCL).

Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting

Biogen

Medicare on Thursday announced plans for coverage of new Alzheimer's drugs whose accessibility has become a point of controversy.

Medicare unveils plan for coverage of new Alzheimer's drugs

Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump

Johnson & Johnson

Novartis

Roche Holding AG

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

AI has taken the world by storm this year. The key reason is that AI might disrupt a wide variety of industries.

News for Eli Lilly Stock (LLY)